A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Raju Kandimalla, Department of Pathology, Erasmus MC, Rotterdam, the Netherlands.
  • ,
  • Roy Masius
  • ,
  • Willemien Beukers
  • ,
  • Chris H Bangma
  • ,
  • Torben F Orntoft
  • Lars Dyrskjot
  • Nikki van Leeuwen
  • ,
  • Hester Lingsma
  • ,
  • Angela A G van Tilborg
  • ,
  • Ellen C Zwarthoff
DNA methylation is associated with bladder cancer and these modifications could serve as useful biomarkers. FGFR3 mutations are present in 60% to 70% of non-muscle invasive bladder cancer (NMIBC). Low-grade bladder cancer recurs in more than 50% of patients. The aim of this study is to determine the sensitivity and specificity of a urine assay for the diagnosis of recurrences in patients with a previous primary NMIBC G1/G2 by using cystoscopy as the reference standard.
Original languageEnglish
JournalClinical Cancer Research
Pages (from-to)4760-9
Number of pages10
Publication statusPublished - 1 Sep 2013

See relations at Aarhus University Citationformats

ID: 70588930